{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=86",
    "query": {
      "condition": "Safety Study",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 33600,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T20:30:03.017Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04663867",
      "title": "AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Artery Occlusion",
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "AngioSafe Peripheral CTO Crossing System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AngioSafe, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2021-02-03",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • St. Helena, California • Darien, Connecticut + 15 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "St. Helena",
          "state": "California"
        },
        {
          "city": "Darien",
          "state": "Connecticut"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04663867"
    },
    {
      "nct_id": "NCT05596734",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "bivalent BNT162b2 (original/Omi BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "qIRV (22/23)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bIRV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tIRV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1019,
      "start_date": "2022-10-28",
      "completion_date": "2023-12-28",
      "has_results": true,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 59,
      "location_summary": "Athens, Alabama • Phoenix, Arizona • Lake Forest, California + 40 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05596734"
    },
    {
      "nct_id": "NCT05009732",
      "title": "A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "GT0918",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suzhou Kintor Pharmaceutical Inc,",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2021-09-30",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 8,
      "location_summary": "Hialeah, Florida • Lansing, Michigan • Hannibal, Missouri + 5 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Hannibal",
          "state": "Missouri"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05009732"
    },
    {
      "nct_id": "NCT03445663",
      "title": "Study Evaluating AMG 424 in Subjects With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/ Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AMG 424",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2018-07-31",
      "completion_date": "2020-06-19",
      "has_results": false,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03445663"
    },
    {
      "nct_id": "NCT07023614",
      "title": "A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-obstructive Hypertrophic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Ninerafaxstat 200mg MR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Imbria Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2025-10-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 26,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07023614"
    },
    {
      "nct_id": "NCT01848106",
      "title": "A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "pegnivacogin/anivamersen",
          "type": "DRUG"
        },
        {
          "name": "Bivalirudin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regado Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3232,
      "start_date": "2013-09",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-23",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 1,
      "location_summary": "Rapid City, South Dakota",
      "locations": [
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848106"
    },
    {
      "nct_id": "NCT01266616",
      "title": "Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Profectus HIV MAG pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2011-03",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266616"
    },
    {
      "nct_id": "NCT03475706",
      "title": "Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Solabegron immediate release tablets, low dose",
          "type": "DRUG"
        },
        {
          "name": "Solabegron immediate release tablets, high dose",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Velicept Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 438,
      "start_date": "2018-02-19",
      "completion_date": "2019-01-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03475706"
    },
    {
      "nct_id": "NCT06492733",
      "title": "FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Total Occlusion of Artery of the Extremities"
      ],
      "interventions": [
        {
          "name": "FastWire System - Peripheral",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Versono Medical Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 65,
      "start_date": "2024-11-05",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 6,
      "location_summary": "Wilmington, Delaware • Cocoa, Florida • Davenport, Iowa + 3 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Cocoa",
          "state": "Florida"
        },
        {
          "city": "Davenport",
          "state": "Iowa"
        },
        {
          "city": "Gray",
          "state": "Louisiana"
        },
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06492733"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-11-21T20:30:03.017Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    }
  ]
}